(Image source: theguardian.com) Shares of Novartis AG (ADR) (NYSE:NVS) are trading higher this morning on news that the company ended a heart drug trail early after the drug yielded strong results. Patients who suffered from chronic heart failure after taking the drug lived longer without frequent visits to hospitals. Novartis will now seek approval from global regulators. Heart disease plagues more than 20 million people globally.